SCOTTSDALE, AZ,--(MARKET WIRE)--Jun 27, 2007 -- HEPI Pharmaceuticals, Inc., a subsidiary of Health Enhancement Products, Inc. (OTC BB:HEPI.OB - News), the makers of ProAlgaZyme®, announced today the filing of a Provisional Application for Patent in the United States. The application is the result of recent discoveries building on research over the past several years on the chemical and biological analysis of ProAlgaZyme®. These discoveries, including newly identified components, shed light on recent results of clinical trials which indicate that ProAlgaZyme has the potential to reduce key markers of inflammation by 57% on average. The patent filing is designed to help protect the potential pharmaceutical opportunities represented by the potential active components of ProAlgaZyme®.
